Cited 4 times in
Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 민유홍 | - |
dc.date.accessioned | 2015-04-23T17:47:51Z | - |
dc.date.available | 2015-04-23T17:47:51Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0041-1345 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/103151 | - |
dc.description.abstract | This study was performed to determine the feasibility of second hematopoietic stem cell transplantation (HSCT) using reduced-intensity conditioning (RIC) with fludarabine and melphalan in patients with relapsed hematologic malignancies after a prior autologous HSCT. Twelve patients (multiple myeloma [n = 7], non-Hodgkin lymphoma [n = 3], and acute myeloid leukemia [n = 2] received allogeneic HSCT using RIC with fludarabine (25 mg/m(2) for 5 days) and melphalan (140 mg/m(2) for 1 day) after a failed autologous HSCT. The graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine plus a minidose of methotrexate. All patients achieved a neutrophil and platelet engraftment in a median 13.5 days and 17.5 days, respectively. The transplant-related mortality was 2 patients (16.7%). Grade II-IV acute GVHD and chronic extensive GVHD were noted in 4 (33.3%) and 1 patient (11.1%), respectively. Over a median follow-up duration of 376 days, 5 patients were alive without evidence of disease. The estimated nonrelapse mortality at 1 year was 28.4%. The estimated overall survival rate at 1 year was 58.3%, and the estimated event-free survival rate at 1 year was 41.7%. Allogeneic HSCT using RIC with fludarabine and melphalan appears to be feasible for a second HSCT in patients with relapsed hematologic malignancies after a failed autologous HSCT | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 3723~3728 | - |
dc.relation.isPartOf | TRANSPLANTATION PROCEEDINGS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Feasibility Studies | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Graft vs Host Disease/etiology | - |
dc.subject.MESH | Hematopoietic Stem Cell Transplantation*/adverse effects | - |
dc.subject.MESH | Hematopoietic Stem Cell Transplantation*/mortality | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Leukemia, Myeloid, Acute/mortality | - |
dc.subject.MESH | Leukemia, Myeloid, Acute/surgery* | - |
dc.subject.MESH | Lymphoma, Non-Hodgkin/mortality | - |
dc.subject.MESH | Lymphoma, Non-Hodgkin/surgery* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Melphalan/adverse effects | - |
dc.subject.MESH | Melphalan/therapeutic use* | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Multiple Myeloma/mortality | - |
dc.subject.MESH | Multiple Myeloma/surgery* | - |
dc.subject.MESH | Myeloablative Agonists/adverse effects | - |
dc.subject.MESH | Myeloablative Agonists/therapeutic use* | - |
dc.subject.MESH | Recurrence | - |
dc.subject.MESH | Reoperation | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Salvage Therapy | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Transplantation Chimera | - |
dc.subject.MESH | Transplantation Conditioning/adverse effects | - |
dc.subject.MESH | Transplantation Conditioning/methods* | - |
dc.subject.MESH | Transplantation, Autologous | - |
dc.subject.MESH | Treatment Failure | - |
dc.subject.MESH | Vidarabine/adverse effects | - |
dc.subject.MESH | Vidarabine/analogs & derivatives* | - |
dc.subject.MESH | Vidarabine/therapeutic use | - |
dc.title | Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | J.Y. Hong | - |
dc.contributor.googleauthor | M.K. Choi | - |
dc.contributor.googleauthor | D.H. Kim | - |
dc.contributor.googleauthor | S.J. Kim | - |
dc.contributor.googleauthor | K. Kim | - |
dc.contributor.googleauthor | W.S. Kim | - |
dc.contributor.googleauthor | C.W. Chung | - |
dc.contributor.googleauthor | H.O. Kim | - |
dc.contributor.googleauthor | Y.H. Min | - |
dc.contributor.googleauthor | J.H. Jang | - |
dc.identifier.doi | 10.1016/j.transproceed.2010.09.005 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01407 | - |
dc.relation.journalcode | J02755 | - |
dc.identifier.eissn | 1873-2623 | - |
dc.identifier.pmid | 21094846 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S004113451001331X | - |
dc.contributor.alternativeName | Min, Yoo Hong | - |
dc.contributor.affiliatedAuthor | Min, Yoo Hong | - |
dc.citation.volume | 42 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 3723 | - |
dc.citation.endPage | 3728 | - |
dc.identifier.bibliographicCitation | TRANSPLANTATION PROCEEDINGS, Vol.42(9) : 3723-3728, 2010 | - |
dc.identifier.rimsid | 35725 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.